Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05USQ
|
|||
| Drug Name |
Nintedanib
|
|||
| Synonyms |
Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; G6HRD2P839; 1160294-26-7; CHEBI:85164; Nintedanib
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H33N5O4
|
|||
| Canonical SMILES |
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
|
|||
| InChI |
1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
|
|||
| InChIKey |
CPMDPSXJELVGJG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 656247-17-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:85164
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832 | |||
| REF 2 | ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.